These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29288596)

  • 1. Ultrasound-Enhanced Drug Delivery for Treatment of Onychomycosis.
    Kline-Schoder A; Le Z; Zderic V
    J Ultrasound Med; 2018 Jul; 37(7):1743-1752. PubMed ID: 29288596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound-Enhanced Ciclopirox Delivery for Treatment of Onychomycosis.
    Kline-Schoder A; Le Z; Zderic V
    Annu Int Conf IEEE Eng Med Biol Soc; 2018 Jul; 2018():5717-5720. PubMed ID: 30441634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-mediated nail drug delivery system.
    Abadi D; Zderic V
    J Ultrasound Med; 2011 Dec; 30(12):1723-30. PubMed ID: 22124008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis.
    Donnelly RF; McCarron PA; Lightowler JM; Woolfson AD
    J Control Release; 2005 Mar; 103(2):381-92. PubMed ID: 15763621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Tampucci S; Mailland F
    Br J Dermatol; 2011 Jul; 165(1):99-105. PubMed ID: 21410668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
    McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
    Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
    Bhatt V; Pillai R
    J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled nail delivery of a novel lipophilic antifungal agent using various modern drug carrier systems as well as in vitro and ex vivo model systems.
    Naumann S; Meyer JP; Kiesow A; Mrestani Y; Wohlrab J; Neubert RH
    J Control Release; 2014 Apr; 180():60-70. PubMed ID: 24560884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation development and optimization of transungual drug delivery system of terbinafine hydrochloride for the treatment of onychomycosis.
    Patel MM; Vora ZM
    Drug Deliv Transl Res; 2016 Jun; 6(3):263-75. PubMed ID: 26926242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmaceutics perspective on drug delivery to the nail: recent advances and challenges.
    Delgado-Charro MB
    Ther Deliv; 2015 Jul; 6(7):773-5. PubMed ID: 26228770
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
    Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of human nail etching for the assessment of topical onychomycosis therapies.
    Repka MA; Mididoddi PK; Stodghill SP
    Int J Pharm; 2004 Sep; 282(1-2):95-106. PubMed ID: 15336385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Ultrasound-Mediated Drug Delivery for Treatment of Onychomycosis.
    Kline-Schoder A; Le Z; Sweeney L; Zderic V
    J Am Podiatr Med Assoc; 2019 Oct; ():. PubMed ID: 31647309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into drug delivery across the nail plate barrier.
    Saner MV; Kulkarni AD; Pardeshi CV
    J Drug Target; 2014 Nov; 22(9):769-89. PubMed ID: 24964054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel nail penetration enhancer containing vesicles "nPEVs" for treatment of onychomycosis.
    Bseiso EA; Nasr M; Sammour OA; Abd El Gawad NA
    Drug Deliv; 2016 Oct; 23(8):2813-2819. PubMed ID: 26447337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ungual and transungual drug delivery.
    Shivakumar HN; Juluri A; Desai BG; Murthy SN
    Drug Dev Ind Pharm; 2012 Aug; 38(8):901-11. PubMed ID: 22149347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.